AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT BROOKLYN IMMUNOTHERAPEUTICS, INC.Executive Employment Agreement • May 31st, 2022 • Brooklyn ImmunoTherapeutics, Inc. • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) dated as of May 10, 2022, is entered by and between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Jackson, an individual residing in Cardiff, California 92007 (“Executive”) and, except with respect to the amendment and restatement hereof contained in the Recitals (which are incorporated by reference and made an operative part of this Agreement), will become effective as of the date on which Executive commences his employment with the Company (the “Effective Date”). Each of the Company and Executive is a “Party,” and collectively, they are the “Parties.”
May 25, 2022Brooklyn ImmunoTherapeutics, Inc. • May 31st, 2022 • Pharmaceutical preparations • New York
